U.S. Recarbrio Withdrawal Raises Antibiotic Access Questions; Canada Still Lists It as Marketed

Merck has told the University of Minnesota’s CIDRAP News that it will stop manufacturing and marketing Recarbrio in the United States. The company described the decision as part of a portfolio review, not a product-safety or quality issue. CIDRAP’s September 29 reporting included fresh, differing views from infectious-disease and antibiotic-access specialists about the clinical and market consequences.

Recarbrio combines imipenem, cilastatin and relebactam. Some experts interviewed by CIDRAP see a narrow but real loss for difficult-to-treat infections; another questions how distinct the product was from alternatives. The broader tension is familiar to antimicrobial-stewardship teams: reserving newer agents for patients who need them limits use, while low sales can undermine commercial supply. Those are expert assessments, not evidence that every hospital will face the same gap.

The U.S. announcement is not a Canadian discontinuation notice. Health Canada’s Drug Product Database lists Recarbrio (DIN 02565323) as “Marketed,” with a status date of May 7, 2026. That administrative listing does not establish current wholesaler inventory or future Canadian supply. Merck’s U.S. decision should not be presented to Canadian patients as a domestic shortage without separate confirmation.

What is known about the clinical gap

CIDRAP’s interviews do not describe a universal loss of treatment options. Infectious-disease specialist Amesh Adalja characterized the gap as narrow but immediate and pointed to other agents for some carbapenem-resistant Enterobacterales infections. He identified difficult-to-treat Pseudomonas aeruginosa as an area where losing imipenem–relebactam could matter more. Another specialist, Brad Spellberg, questioned whether the product was sufficiently differentiated from alternatives. Those are contrasting expert judgments in the CIDRAP report, not a substitute for local susceptibility data or formulary review. An individual hospital’s effect will depend on the organisms it sees, its testing capabilities and the agents it can actually obtain.

Why a low-use antibiotic can be hard to sustain

Reserve antibiotics are intentionally used sparingly: stewardship teams try to preserve their effectiveness and choose them for patients whose infection and susceptibility profile warrant them. CIDRAP also describes the commercial tension this creates for manufacturers—limited sales may not support continued marketing even when a product retains clinical value for a small group of patients. That broader access issue is distinct from Merck’s stated reason for the U.S. decision, which it described as a portfolio review. It does not establish that Canadian supply is ending or that a Canadian hospital should switch therapy today.

For a Canadian institution, three separate checks are therefore necessary before making an access claim: current regulatory status, actual local procurement or wholesaler availability, and the patient-specific clinical alternatives. Health Canada’s “Marketed” entry answers only the first of these. A manufacturer or provincial shortage notice would be needed to establish a domestic supply change.

Practice considerations

• For a patient or institution asking about access, distinguish U.S. withdrawal from Canadian regulatory status and actual local stock.
• Check current manufacturer, wholesaler and institutional supply information before giving a Canadian availability answer.
• Keep antimicrobial selection tied to organism, susceptibility, site of infection and specialist stewardship guidance; this report is not a substitution guide.
• Flag any emerging access problem through the appropriate procurement and shortage channels rather than assuming it follows automatically from U.S. news.
• Preserve stewardship documentation when using reserve agents, while recognizing that access policy is a separate system-level question.

The story is about a U.S. market decision and the access debate it has reopened, not a change to the Canadian product monograph or a new treatment recommendation.